Dronedarone in high-risk permanent atrial fibrillation
Journal
The New England journal of medicine
Journal Volume
365
Journal Issue
24
Pages
2268
Date Issued
2011-12-15
Author(s)
Connolly, Stuart J
Camm, A John
Halperin, Jonathan L
Joyner, Campbell
Alings, Marco
Amerena, John
Atar, Dan
Avezum, Álvaro
Blomström, Per
Borggrefe, Martin
Budaj, Andrzej
Chen, Shih-Ann
Ching, Chi Keong
Commerford, Patrick
Dans, Antonio
Davy, Jean-Marc
Delacrétaz, Etienne
Di Pasquale, Giuseppe
Diaz, Rafael
Dorian, Paul
Flaker, Greg
Golitsyn, Sergey
Gonzalez-Hermosillo, Antonio
Granger, Christopher B
Heidbüchel, Hein
Kautzner, Josef
Kim, June Soo
Lanas, Fernando
Lewis, Basil S
Merino, Jose L
Morillo, Carlos
Murin, Jan
Narasimhan, Calambur
Paolasso, Ernesto
Parkhomenko, Alexander
Peters, Nicholas S
Sim, Kui-Hian
Stiles, Martin K
Tanomsup, Supachai
Toivonen, Lauri
Tomcsányi, János
Torp-Pedersen, Christian
Tse, Hung-Fat
Vardas, Panos
Vinereanu, Dragos
Xavier, Denis
Zhu, Jun
Zhu, Jun-Ren
Baret-Cormel, Lydie
Weinling, Estelle
Staiger, Christoph
Yusuf, Salim
Chrolavicius, Susan
Afzal, Rizwan
Hohnloser, Stefan H
Abstract
Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation.
Type
journal article